Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1825351 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TDP1MAPK1LMNATRPA1 | |
| SCHEMBL11221544 | 0.88 | TDP1 (0.43) | ALDH1A1TDP1MAPK1CYP2C19L3MBTL1 | |
| SCHEMBL11221549 | 0.88 | TDP1 (0.43) | ALDH1A1TDP1MAPK1CYP2C19L3MBTL1 | |
| SCHEMBL376723 | 0.83 | ALDH1A1 (0.48) | ALDH1A1TDP1MAPK1LMNACYP2C19 | |
| SCHEMBL9421100 | 0.78 | CES2 (0.43) | CYP2C19MAPTCYP1A2CES1CES2 | |
| SCHEMBL9421046 | 0.78 | CES2 (0.43) | CYP2C19MAPTCYP1A2CES1CES2 | |
| SCHEMBL13825219 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TDP1MAPK1LMNATRPA1 | |
| SCHEMBL9421038 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNAMAPTNPSR1 | |
| SCHEMBL30698175 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TDP1MAPK1LMNATRPA1 | |
| SCHEMBL9421036 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234455-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2010-09-16 | — | — | US | disclosed |
| US-5332857-A | 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents | PFIZER INC. (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0312269-B1 | 3,5-DIHYDROXY-6,8-NONADIENOIC ACIDS AND DERIVATIVES AS HYPOCHOLESTEROLEMIC AGENTS | PFIZER INC. (US) | 1993-06-16 | — | — | EP | disclosed |
| US-5151545-A | 3,5-DIHYDROXY-6,8-NONADIENOIC ACIDS AND DERIVATIVES AS HYPOCHOLESTEROLEMIC AGENTS | PFIZER INC. (US) | 1992-09-29 | — | — | US | disclosed |
| WO-1989003212-A1 | 3,5-DIHYDROXY-6,8-NONADIENOIC ACIDS AND DERIVATIVES AS HYPOCHOLESTEROLEMIC AGENTS | PFIZER INC. (US) | 1989-04-20 | — | — | WO | disclosed |
| EP-0312269-A2 | 3,5-Dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents | PFIZER INC. (US) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234455-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | ALDH1A1 1607/4885TDP1 3441/4885MAPK1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.